Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > total ballpark deal value

<< Previous

Bullboard Posts

Next >>

Comment by SironaInvestoron Sep 29, 2022 12:00pm

112 Views

Post# 34995045

RE:RE:RE:RE:RE:total ballpark deal value

Biorun, unbelievable how you still support the management. Nobody knows the true value of this deal independent of a high or low upfront. Remember, Sirona started to promote the compound as an alternative to lighten the skin in a 25 billion market. Now, we are in a 8 billion hyperpigmentation market and sold it with exclusive rights. So a new Goldstandard should reflect high commercial value but we simply do not know it. That's unbelievable. Tonight we will see the next desaster, maybe with the information to have an overscribed Capital increase?

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China